A Multicenter Study to Evaluate the Long-term Safety and Tolerability of Open-label LCZ696 in Patients With Acute Myocardial Infarction Who Previously Participated in CLCZ696G2301 (PARADISE-MI)
Latest Information Update: 15 Sep 2023
Price :
$35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharmaceuticals
- 04 Dec 2021 This trial has been discontinued in Greece , according to European Clinical Trials Database record.
- 16 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Aug 2021 This trial has been discontinued in Sweden (End Date: 27 Apr 2021), according to European Clinical Trials Database record.